NCT05608876进行中（未招募）2 期
A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
- 试验地点
- 7
- 主要终点
- Tumour Response
研究概览
简要总结
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
详细描述
Primary Objective
- To evaluate tumour ablation following treatment(s) with intratumoural injections of tigilanol tiglate.
Secondary Objectives
- To assess the safety and tolerability of intratumoural injections with tigilanol tiglate.
- To evaluate disease control by assessing time to local disease recurrence from last treatment.
- To evaluate the tumour recurrence rate at injected tumour sites.
- To evaluate survival by assessing Progression Free Survival (PFS).
Exploratory Objectives
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are willing and able to provide written informed consent for the study prior to any protocol-specific procedures and to comply with all local and study requirements.
- •Are ≥ 18 years of age on the day of providing informed consent.
- •Have a histologically confirmed diagnosis of a solid head and neck malignancy and have either recurrent disease and/or metastatic disease, or have failed on at least one line of systemic therapy. Tumour types can include: HNSCC, sino-nasal cancers, salivary gland cancers, and peri-stomal laryngeal carcinomas with pre-existing tracheostomy.
- •Have disease that is amenable to intratumoural injection either by palpation or under ultrasound guided injection. Lymph nodes with metastatic disease from the patient's head and neck cancer can be selected for treatment. Note: Measurable disease as per RECIST v1.
- •is not mandatory.
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Have life expectancy of more than 12 weeks.
- •Female participants who are Women of Child-Bearing Potential (WOCBP) must have a negative serum pregnancy test at Screening (within 14 days of the first study drug administration), must be willing to use a highly effective contraception from date of consent, throughout the study period and up to 30 days after the last study drug administration, and must not be breastfeeding.
- •Male participants with a potentially fertile female partner are eligible if they have had a vasectomy or are willing to use adequate contraception from prior to commencement of study drug administration, throughout the study period and up to 30 days after the last study drug administration, and must not donate sperm throughout the study period and up to 30 days after the last study drug administration.
排除标准
- •Are planning to receive intratumoural treatment or radiotherapy to any of the tumours intended for injection within 28 days prior to Screening, or during treatment with tigilanol tiglate.
- •Have a tumour intended for injection that is immediately adjacent to, or with infiltration into, any major artery or vein (e.g., if the tumour for injection is located adjacent to the jugular vein).
- •Have a tumour intended for injection located in an area where post-injection swelling could compromise the airway.
- •Have a tumour intended for injection that is a nasal tumour extending into the Ethmoid sinus.
- •Have had any previous intervention (extensive surgery or radiation therapy) in the area of a tumour intended for injection that is in proximity of the airway (such that tracking of the injected fluid may be unpredictable and could lead to airway swelling). Patients with a permanent tracheostomy can be included.
- •Are receiving or have received other investigational agents or have used an investigational device without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate. These patients must have recovered from all AEs due to previous investigational therapies to ≤ Grade 1 at baseline.
- •Are receiving or have received systemic anticancer therapy, or therapeutic radiation treatment, without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate. These patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 at baseline.
- •Have had major surgery within 28 days of their first treatment with tigilanol tiglate or anticipate the need for major surgery during the study period. Minor surgical procedures are permitted, but with sufficient time for wound healing.
- •Have known, current or history of active cerebral metastasis and/or carcinomatous meningitis.
- •Have any bleeding diathesis or coagulopathy that would make intratumoural injection or biopsy unsafe, or if they are on therapeutic warfarin therapy.
- •Have a history of allergic reactions or severe hypersensitivity (Grade ≥ 3) attributed to tigilanol tiglate or compounds of similar chemical or biologic composition to tigilanol tiglate, any of its excipients or other agents used in the study.
- •In the opinion of the treating Investigator, the patient is not an appropriate candidate for the study for any reason (e.g., they have a known psychiatric or substance abuse disorder that would interfere with their ability to cooperate with the requirements of the study).
研究组 & 干预措施
Single Arm, Open Label
Experimental
Single or multiple Intratumoural injections of tigilanol tiglate at up to a fixed dose of 3.6 mg/m2 (Body Surface Area [BSA]) per treatment.
干预措施: Tigilanol Tiglate (Drug)
结局指标
主要结局
Tumour Response
时间窗: 72 weeks
Proportion of participants who have achieved partial or complete ablation of treated tumour(s) and/or tumour segment(s) following injection(s) with tigilanol tiglate.
次要结局
- Progression Free Survival (PFS)(72 weeks)
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)(72 weeks)
- Disease Control(72 weeks)
- Local Recurrence Rate at injection site(s)(6-, 12-, and 18-months after first treatment.)
研究者
研究点 (7)
Loading locations...
相似试验
招募中
2 期
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue SarcomaSoft Tissue SarcomaNCT05755113QBiotics Group Limited40
已完成
2 期
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsPD-L1-selected Solid TumorsNCT05661578Hoffmann-La Roche64
已完成
2 期
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaFollicular LymphomaNCT03568461Novartis Pharmaceuticals98
进行中（未招募）
3 期
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Hepatocellular CarcinomaNCT05904886Hoffmann-La Roche687
进行中（未招募）
1 期
Study of BO-112 with pembrolizumab for colorectal or gastric /gastro-oesophageal junction cancer with liver metastasisColorectal cancer or gastric/gastro-oesophageal junction cancer with liver metastasisMedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004624-38-ESBioncotech Therapeutics, S.69